BioSpace News Archive

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported top line data from the randomized Phase 2 SELECT trial evaluating vopratelimab (vopra).

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 7116547) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the Japanese Patent Office.

Genetic Technologies Limited, a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2022.

Aristea Therapeutics today announced the dosing of the first patient in its Phase 2a trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of hidradenitis suppurativa (HS).

Seelos Therapeutics, Inc. today announced that it will participate in two upcoming psychedelic conferences.

Indica Labs The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics ( iCAIRD ), announced today an agreement to collaborate on the development of an AI-based digital pathology solution for the detection of cancer within lymph nodes from colorectal surgery cases.

Cybin Inc. is pleased to announce that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder.

Parse Biosciences announced today a significant performance update of its chemistry for the Evercode™ Whole Transcriptome products.

Biomerica, Inc. announced plans to launch its InFoods® IBS test before calendar year end.

Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo” or the “Company”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced today an initial corporate and business update since re-establishing fully available commercial operations in the second quarter of this year.